N4 Pharma Nuvec® has Considerable Potential in Developing Novel Cancer Treatments (VIDEO)

N4 Pharma plc (LON:N4P) CEO Nigel Theobald joins DirectorsTalk Interviews to discuss an update on its research & development and strategy.

In this interview Nigel talks us through the latest results and what they mean for the Company, explains how they are maintaining cell inhibition with a lower observed knockdown of the siRNA, how Nuvec will be used clinically in this space and what else investors can expect over the coming months.

N4 Pharma Plc is a specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines. For more information visit: https://investors.n4pharma.com/

Find more news, interviews, share price & company profile here for:

    Share this interview

    Twitter
    LinkedIn
    Facebook
    Email
    WhatsApp